Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size

Price

Stock

Quantity

100mg	USD 97	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (832) 582-8158 [email protected]

Cited by 26 Publications

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )
J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	M2rLUmZ2dmO2aX;uJGF{e2G7	M2jye\|AvOS1\|MDFOwG0>	NVfs[mtHPDhiaB?=		MVrpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	M3uwdVI3PTF\|MUey
H460	M2SyPGZ2dmO2aX;uJGF{e2G7	MYewMlEuOzBizszN	NVWzZmFtPDhiaB?=		MYrpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	MlHMNlY2OTNzN{K=
HKESC-2	NFnCVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLUNlDDqM7:TR?=	NEW3TFY1QMLiaNMg		NIT0SZh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW\|IH;mJI95[WyrcHzheIlvyqB?	Mk\VNlY1PzR4OUO=
CaES-17	M3H1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXDNlDDqM7:TR?=	NXew[HNqPDkEoHlCpC=>		MYrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA>	NHvDc2wzPjR5NE[5Ny=>
HKESC-2	NWHpcWtNSXCxcITvd4l{KEG\|c3H5	MXeyNOKh\|ryP	Ml36OFjDqGkEoB?=		NELIUpBz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NXfsNlM2OjZ2N{S2PVM>
CaES-17	NYH4TZVzSXCxcITvd4l{KEG\|c3H5	NEPFemwzOMLizszN	M3HjSlQ5yqCqwrC=		NEfCbZJz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NVXRZ\|B1OjZ2N{S2PVM>
A549	M{TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWG1MVE3OCEQvF2=	NWnwXVlJPDkEoHlCpC=>	MnfoSG1UVw>?	NFXIeFhKSzVyPUG2N{41KM7:TR?=	MWiyOlQ3PDZ2Mx?=
HCC827	NF;5VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PrbFUuOTZyIN88US=>	MmXHOFjDqGkEoB?=	MonNSG1UVw>?	NEf1T3lKSzVyPU[5MlIh\|ryP	MUiyOlQ3PDZ2Mx?=
A549	NHXaV5FCeG:ydH;zbZMhSXO\|YYm=	NXu0NIN6QDBiwsXN	NEj5VmQ1QMLiaNMg	MmHZSG1UVw>?	Ml3mbY5lfWOnczDhdI9xfG:\|aYO=	Mlm5NlY1PjR4NEO=
HCC827	NH3s[JdCeG:ydH;zbZMhSXO\|YYm=	MUm4NEDDvU1?	NEHLUXI1QMLiaNMg	MXPEUXNQ	NEPVfIRqdmS3Y3XzJIFxd3C2b4Ppdy=>	MXyyOlQ3PDZ2Mx?=
SGC-7901/DDP	M1jFemZ2dmO2aX;uJGF{e2G7	NFrvW44yOMLiwsXN	MY[yOEBp		Mk\EbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW\|c3nvci=>	NInKPJgzPjRyN{[1Ny=>
SGC-7901	M1P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NI\qSnQzPMLiaNMg		M1zGc2lEPTB;MUG1MlA5KM7:TR?=	MXWyOlQxPzZ3Mx?=
SGC-7901/DDP	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MknWNlTDqGkEoB?=		NHu3bVNKSzVyPUO1MlQ2KM7:TR?=	MmnENlY1ODd4NUO=
SGC-7901/DDP	M3jqPWFxd3C2b4Ppd{BCe3OjeR?=	NEDBSG0yOMLiwsXN	NHTifYUzPCCq		MmHJbY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=>	NWXS[mxsOjZ2MEe2OVM>
SGC-7901/DDP	MVnGeY5kfGmxbjDBd5NigQ>?	NULOTpBpOTEEoNM1US=>	MYGyOEBp		M1z6bIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi	MUKyOlQxPzZ3Mx?=
SGC-7901/DDP	MWLGeY5kfGmxbjDBd5NigQ>?	MkS3NVDDqML3TR?=	Moi4NlQhcA>?		NF\sS5Jk[XW\|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4>	MnPXNlY1ODd4NUO=
H357	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\YWHB2Py53L{GwJO69VQ>?	M3zl[lQ5KGh?	MlnESG1UVw>?	NXjrW4FEcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>?	NYG2VJdUOjZyMEm4O\|Q>
TAF	MXrGeY5kfGmxbjDBd5NigQ>?	NI\zbosyOMLiwsXN	NFSzfZM4KGR?		MkfPZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN?	MWSyOVk5PzF{Nx?=
TAF	MX7GeY5kfGmxbjDBd5NigQ>?	MYGxNOKhyrWP	MXqzNE0yOjBibXnu		NYi5WI9{eG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o	MV2yOVk5PzF{Nx?=
TAF	MW\GeY5kfGmxbjDBd5NigQ>?	NFrSc5EyOMLiwsXN	M2PRT\|Q5KGh?		NGm3[ZZqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	MnnDNlU6QDdzMke=
PANC-1	M1y2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3r0ZlIxNzZyL{GwNEDPxE1?	MV6yOE81QC95MjDo		MmjZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MonCNlU6PzNyNkK=
PANC-1	NEH4d3hHfW6ldHnvckBCe3OjeR?=	MlvnNlAwPjBxMUCwJO69VQ>?	NF[2W\|gzPCCq		NIfRWmlifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	MkTqNlU6PzNyNkK=
HeLa	NWnqOIRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITRSWozOMLizszNxsA>	NHzTO4YzPMLiaB?=		NWjZ[HdU\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36=	NIXCbXAzPTd5MESyNy=>
SACC-83	NI\u[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUiyNOKh\|ryPwrC=	MmTUNlTDqGh?		MoPx[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25?	NFHmNngzPTd5MESyNy=>
HeLa	NVHw[JdvSXCxcITvd4l{KEG\|c3H5	MVuyNOKh\|ryPwrC=	M2Lwb\|I1yqCq		M2jUXoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM>	MWGyOVc4ODR{Mx?=
SACC-83	MnnZRZBweHSxc3nzJGF{e2G7	M3zG[lIxyqEQvF5CpC=>	M{TuXVI1yqCq		Mmry[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>	NUG4Xmd6OjV5N{C0NlM>
HeLa	NVzCV4FDTnWwY4Tpc44hSXO\|YYm=	Ml\GNlAwPDBxOECg{txO	M2nFb\|I1yqCq		MXr1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW\|IFHLWC=>	NYDPdpJZOjV5N{C0NlM>
SACC-83	MkD6SpVv[3Srb36gRZN{[Xl?	NGnsVXczOC92MD:4NEDPxE1?	NVqycGUyOjUEoHi=		NGP3V2t2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	MkLENlU4PzB2MkO=
HLCZ01	NVrab2tjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX6wWmlKOOLCk{[wxsDDvU1?	NETITG81QCCq	MnjHSG1UVw>?	NYTTfJhUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MYKyOVczPDh7OR?=
HLCZ01	MYTGeY5kfGmxbjDBd5NigQ>?	M1L3b\|QxyqEQvF2=	M{P0bVI1KGh?	NIHTfnlFVVOR	NWPXeYVycW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	MlTlNlU4OjR6OUm=
HLCZ01	M4LsVGFxd3C2b4Ppd{BCe3OjeR?=	MX20NOKh\|ryP	NXu2fYhHOjRiaB?=	MmXmSG1UVw>?	NEjKeWpmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u\|rF?	MoXpNlU4OjR6OUm=
HLCZ01	NUG0b4pZTnWwY4Tpc44hSXO\|YYm=	M{PodlQxyqEQvF2=	M3LSWlI1KGh?	MnTlSG1UVw>?	NXy3dWZHcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y	MXiyOVczPDh7OR?=
MGC803	M4nZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MViwMVYxKM7:TR?=	M4XJd\|czKGh?		MX\JR\|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?=	MnPxNlU4ODF\|N{i=
SGC7901	NHHFU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWmwMVYxKM7:TR?=	M3\Oc\|czKGh?		NHO0VJhKSzVyPUSzMlU{6oDLwsJihKk2NjF{IN88US=>	MmLINlU4ODF\|N{i=
MGC803	M{C5O2Z2dmO2aX;uJGF{e2G7	NGHUfGU1OMLizszN	M4f5UVgwOTZxMkSgbC=>		NUDrZWg4fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	NVf6enZROjV5MEGzO\|g>
SGC7901	Mn7vSpVv[3Srb36gRZN{[Xl?	Ml\ROFDDqM7:TR?=	MU[4M\|E3NzJ2IHi=		NXzFe5FXfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	NWDz[5UzOjV5MEGzO\|g>
MCF-7	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vCVlEwOTBizszN	M4HBV\|czKGh?	MWjEUXNQ	NXW3OlVL\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36=	MnjLNlU3Pjd3MUC=
MDA-MB-231	M2fDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfUWHJPOS9zMDFOwG0>	MlnwO\|IhcA>?	NHTKZmRFVVOR	NEfifHpmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	MknoNlU3Pjd3MUC=
MDA-MB-231	NEHCS2FHfW6ldHnvckBCe3OjeR?=	MY[wMVQxKML3TR?=	NHnMXmc1NTJ2IHi=		M3fVO4lv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MVWyOVU5PzN{OR?=
MCF-7	MVzGeY5kfGmxbjDBd5NigQ>?	NUTJTYhqOC12MDFCuW0>	NV7QTFFiPC1{NDDo		MVjlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	M1y5cVI2PTh5M{K5
MCF7-MX	NHzNeo5HfW6ldHnvckBCe3OjeR?=	MmTtNE01OCEEtV2=	NImzfXg1NTJ2IHi=		NF7rb5VmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS\|Ih\XiycnXzd4lwdsLi	MV[yOVU5PzN{OR?=
MDA-MB-231	MWDGeY5kfGmxbjDBd5NigQ>?	M4rEbFAuPDBiwsXN	MV:0MVI1KGh?		NEfXSpB{fGmvdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=	MUCyOVU5PzN{OR?=
A2780	M3XOcGZ2dmO2aX;uJGF{e2G7	MX61M\|ExNzF3IN88US=>	MUG0PEBp		M333RYRm[3KnYYPld{BEd3hvMjDlfJBz\XO\|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1:wS\|I2PDJ2OEm4
SKOV3	MYrGeY5kfGmxbjDBd5NigQ>?	NFPWTng2NzFyL{G1JO69VQ>?	NETqflM1QCCq		MmXu[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGrk[VMzPTR{NEi5PC=>
A2780	MmDhSpVv[3Srb36gRZN{[Xl?	NXXoRm5mPS9zMD:xOUDPxE1?	NXTjRZExPDhiaB?=		MULlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv	Mk\2NlU1OjR6OUi=
SKOV3	NWHvepVnTnWwY4Tpc44hSXO\|YYm=	MV21M\|ExNzF3IN88US=>	Mn\tOFghcA>?		NYLHd\|RX\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?=	NEPCVG8zPTR{NEi5PC=>
A2780	MY\GeY5kfGmxbjDBd5NigQ>?	NYjYO4tIPS9zMD:xOUDPxE1?	NGPGbGo1QCCq		NXOycIxz\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu	NI\sRowzPTR{NEi5PC=>
SKOV3	NV\jZnhxTnWwY4Tpc44hSXO\|YYm=	NHfwT\|Q2NzFyL{G1JO69VQ>?	NEe0V\|c1QCCq		NVXvO4pK\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu	MnLwNlU1OjR6OUi=
A2780	M3npT2Z2dmO2aX;uJGF{e2G7	NXjGVFVOPS9zMD:xOUDPxE1?	Ml3INUBp		NHvLPJpqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MnPYNlU1OjR6OUi=
SKOV3	Mn;mSpVv[3Srb36gRZN{[Xl?	NID6[WQ2NzFyL{G1JO69VQ>?	MoDqNUBp		MVHpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MmHENlU1OjR6OUi=
HCT-15	MkDnSpVv[3Srb36gRZN{[Xl?	NELZT3kyOC13MDFOwG0>	NX\hbIdGPi1\|NjDo		NVrle3o6cW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MnzxNlUzOThyMki=
HT-29	M1XZPWZ2dmO2aX;uJGF{e2G7	NEjO[ZcyOC13MDFOwG0>	NXzxO3FMPi1\|NjDo		MVXpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	NWDaUpBqOjV{MUiwNlg>
HSC3	NWHXSphDS2WubDDWbYFjcWyrdImgRZN{[Xl?	M{DV[VDjiJN2MDFOwG0>	NIm2[5k1QCCq		NIXxeWpKSzVyPUK1MlXDuTFwN{iwJO69VQ>?	M3vNSFI2OTl6N{i5
HSC3	NYD4TnZGSXCxcITvd4l{KEG\|c3H5	NXPOeJp4OjVizszN	NH3ZZ3c1QCCq		M{\1d4lv\HWlZYOgZZBweHSxc3nz	Ml\aNlUyQTh5OEm=
HSC3	MWTGeY5kfGmxbjDBd5NigQ>?	NEjnV4czPSEQvF2=	M2DRO\|Q5KGh?		NUXHPWRM\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?=	MmPkNlUyQTh5OEm=
HSC3	NWX2boFMTnWwY4Tpc44hSXO\|YYm=	M4qxXVI2KM7:TR?=	NUnvWVc5PDhiaB?=		NX7TcJhMcW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV	NFLudnIzPTF7OEe4PS=>
HSC3	MXLGeY5kfGmxbjDBd5NigQ>?	Mli5NlUh\|ryP	M3nhNFczKGh?		MkS3[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg	NF;ycXkzPTF7OEe4PS=>
201T	NVr1[FZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG\TfG44OiCq	NF7XPGxFVVOR	NHr1N5BKSzVyPUS4MlYhyrWP	Mn;hNlUxPTd7NEG=
273T	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYLLWXU6PzJiaB?=	MWTEUXNQ	MXrJR\|UxRThyLkWgxtVO	M4XxdVI2ODV5OUSx
Hep-2	NVTjbZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DXU\|MxNzVyL{GwNEDPxE1?	M1rERVEzNzJ2L{O2M\|Q5KGh?	MoLRSG1UVw>?	MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MWKyOFk6QDV4NB?=
Hep-2	NFK5SJNCeG:ydH;zbZMhSXO\|YYm=	MY[1NEDPxE1?	NYf2RlRXOC12ODDo	MXzEUXNQ	M1nYVIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy	M4XBWVI1QTl6NU[0
Hep-2	M2HG[GZ2dmO2aX;uJGF{e2G7	M{XCcVUxKM7:TR?=	NXXYfWlpOC12ODDo	NF7BXGVFVVOR	M{fn[JJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7	NILWRoMzPDl7OEW2OC=>
Hep-2	NIr1b5NHfW6ldHnvckBCe3OjeR?=	Mni5OVAh\|ryP	NI\YUJQxNTR6IHi=	NH3ZWWpFVVOR	Mnf0[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ>	M2TGb\|I1QTl6NU[0
SGC-7901	NH3wUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n1UVExNzVyL{GwNEDPxE1?	MkDpNlQwPDhxN{KgbC=>	NUTIUXpUTE2VTx?=	MmGxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NVjtUWJyOjR7OUK5OVg>
MKN-45	M2PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGxNE82OC9zMECg{txO	MU[yOE81QC95MjDo	NV;rSWFuTE2VTx?=	M1u3eolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NELTRXozPDl7Mkm1PC=>
SGC-7901	M1TDTGZ2dmO2aX;uJGF{e2G7	M3rXcFExNzVyL{GwNEDPxE1?	MorpOFghcA>?	NFPvU5NFVVOR	NIHabZFld3ewcnXneYxifGW\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NU[yZpB1OjR7OUK5OVg>
MKN-45	MkSzSpVv[3Srb36gRZN{[Xl?	NGG5[JUyOC93MD:xNFAh\|ryP	MnTWOFghcA>?	MXPEUXNQ	NWjEWW9I\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MVqyOFk6Ojl3OB?=
C666-1	NHroeoFEgXSxdH;4bYNqfHliQYPzZZk>	MV[yNE05OCEQvF2=	Mn\HNlQhcA>?		NX7M[Fkz\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	M13yflI1QDV2OEO4
CNE-1	NUe3TG9KS3m2b4TvfIlkcXS7IFHzd4F6	NEfLZ\|czOC16MDFOwG0>	M2jG[lI1KGh?		NGnnO21l\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	NInwfo4zPDh3NEizPC=>
CNE-2	NX\iOYtIS3m2b4TvfIlkcXS7IFHzd4F6	MV2yNE05OCEQvF2=	NHf2flQzPCCq		MoO0[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=>	MoHiNlQ5PTR6M{i=
C666-1	MkHKR5l1d3SxeHnjbZR6KEG\|c3H5	NIK2Wmk3OCEQvF2=	NXW1R2lXPyCm		MVLlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?=	NIO4VoEzPDh3NEizPC=>
CNE-1	NUDnXWVmS3m2b4TvfIlkcXS7IFHzd4F6	M{LXU\|YxKM7:TR?=	MkDkO{Bl		NYHFVZpq\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	NIHEfGUzPDh3NEizPC=>
SNU-1041	M1e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmP4NE01OCEQvF2=	NXO4WmZtPDhiaB?=		MV3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MlvkNlQ3QTJ5MEO=
SNU-1041	MlnoSpVv[3Srb36gRZN{[Xl?	MWOyNE8{OCEQvF2=	MmjQOEBp		MmPtbY5lfWOnczDlfJBz\XO\|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA>	MWGyOFY6OjdyMx?=
SNU-1041	MUjGeY5kfGmxbjDBd5NigQ>?	M1Kwb\|AuPDBizszN	NV3LR4QyPCCq		NVrrSFR1fXBvcnXneYxifGW\|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO=	MY[yOFY6OjdyMx?=
SGC-7901	M3fCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[2NHI2OC1zMkWg{txO	NEL6RYYzPC92OD:3NkBp		MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MUKyOFY4PjN7NB?=
SGC-7901	NEfFeFJCeG:ydH;zbZMhSXO\|YYm=	NVjwdHFJOTByIN88US=>	M160[\|czKGh?		Mn\EbY5lfWOnczDhdI9xfG:\|aYO=	NUWwdGoxOjR4N{[zPVQ>
SGC-7901	MWHGeY5kfGmxbjDBd5NigQ>?	MWO3OU8yODBxMUK1JO69VQ>?	MWKyOE81QC95MjDo		MkfsbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK=	NY[4ZVl6OjR4N{[zPVQ>
LMeC	MUXGeY5kfGmxbjDBd5NigQ>?	NW\RV5dUOjBxNUCg{txO	NEnQbG41QCCq		M4PkWYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw	M1Hjc\|I1PjV4N{S2
CMeC-1	NFz6epdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGLTW2szOC93MDFOwG0>	MXm0PEBp		NF;vU3JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M1S1OVI1PjV4N{S2
LMeC	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4jiU\|IxNzVyIN88US=>	M3TMNFQ5KGh?		NWXZb49ucW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MlfpNlQ3PTZ5NE[=
CMeC-1	MWjGeY5kfGmxbjDBd5NigQ>?	NHTFT24zOC93MDFOwG0>	M4D2[lQ5KGh?		NVjEZZU5cW6mdXPld{BIOS2VIHHydoV{fA>?	NHr2[5EzPDZ3Nke0Oi=>
LMeC	NHf0VIZHfW6ldHnvckBCe3OjeR?=	NFzhV3UzOC93MDFOwG0>	NH;kcGg1QCCq		MYHpcoR2[2W\|IFexMXMh[XK{ZYP0	NXT4VGJIOjR4NU[3OFY>
CMeC-1	M3fue2Z2dmO2aX;uJGF{e2G7	M4HLOVIxNzVyIN88US=>	NFXHe5M1QCCq		NUPBb4s{\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NUfhVWx[OjR4NU[3OFY>
LMeC	M2XRO2Z2dmO2aX;uJGF{e2G7	NIjCPGszOC93MDFOwG0>	MVW0PEBp		M3\0eYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHuzNpozPDZ3Nke0Oi=>
CMeC-1	MWHGeY5kfGmxbjDBd5NigQ>?	M13GfVIxNzVyIN88US=>	NWXTdXV[PDhiaB?=		Mn[2bY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	M3q1O\|I1PjV4N{S2
LMeC	NFziVFlHfW6ldHnvckBCe3OjeR?=	NFHjUXczOC93MDFOwG0>	NFz0RnU1QCCq		NVXQSHRLcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>?	NXHTb3RVOjR4NU[3OFY>
OVCAR-3	NIjENmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFX3R4QyOCEEtV2=	M3vhc\|EhcA>?		Mn3Q[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=>	M4LQRlI1PTJyMkK3
OVCAR-3	MWPBdI9xfG:\|aYOgRZN{[Xl?	NWPVXnFXOTBiwsXN	MnHVNUBp		M3TrUpBzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>?	MkHhNlQ2OjB{Mke=
OVCAR-3	NHLHRYlHfW6ldHnvckBCe3OjeR?=	NV3qZW5bOTBiwsXN	Mk\2NUBp		M1mzcoVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg	M{n6eFI1PTJyMkK3
OVCAR-3	M2G2VWZ2dmO2aX;uJGF{e2G7	NWfDO2JyOTBiwsXN	NX3wZ\|k5OSCq		M{C5XoRwf25vcnXneYxifGW\|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>	M2T0SFI1PTJyMkK3
OVCAR-3	NF3lSZFHfW6ldHnvckBCe3OjeR?=	NX3W[mV3OTBiwsXN	M1LkR\|EhcA>?		MkG1bY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44>	NHTV[o8zPDV{MEKyOy=>
CF33	MX\GeY5kfGmxbjDBd5NigQ>?	MU[xNFAh\|ryP	M2LTO\|I1KGh?		NHX4d2dqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?=	NHu4flMzPDVyM{e4Ni=>
CF33	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjyNVAuOTByIN88US=>	MVWwMVQh\A>?		NYm3[lVkcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M4PRPVI1PTB\|N{iy
CF33	MmLmSpVv[3Srb36gRZN{[Xl?	MW[xNE0yODBizszN	NVO3T4tQPC1{NDDo		M2XNN4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy\|IHnuJGcxN0dzIHHydoV{fA>?	MlzkNlQ2ODN5OEK=
LNCaP	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[yM\|UwOTBizszN	Ml;zPVYhcA>?		NGnseG1qdmirYnn0d{Bk\WyuIHfyc5d1cCC\|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu	MYCyOFI6Pjl5OB?=
LNCaP	NV61bGFlSXCxcITvd4l{KEG\|c3H5	MorUNk82NzFyIN88US=>	MlnUPVYhcA>?		MlzpbY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6=	NX3DUVl3OjR{OU[5O\|g>
PC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPJe5UxNTVyIN88US=>	M4HSUFQ56oDLaB?=		M{DNcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MkHXNlQyOjd6OEK=
PC-3	MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NX\ITphtOC1zMECg{txO	MnS3O\|IhcA>?		Mnru[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NFz3Z3EzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SC 58635

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Not yet recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	June 30 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable
NCT03541655	Active not recruiting	Drug: Bupivacaine HCl\|Drug: F14 (celecoxib)	Total Knee Replacement\|Postoperative Pain	Arthritis Innovation Corporation	May 4 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type